Amicus Therapeutics, Inc.FOLDNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +30.09% | +13.45% | +22.12% | +19.46% | +23.72% |
| Gross Profit Growth | +29.99% | +17.26% | +20.85% | +15.19% | +16.24% |
| EBITDA Growth | +0.00% | +0.00% | -138.94% | +121.09% | -24.92% |
| Operating Income Growth | +0.00% | +0.00% | -163.30% | +58.22% | -0.16% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -88.53% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | -89.05% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | -89.05% |
| Weighted Average Shares Growth | +1.86% | +1.58% | +1.47% | +1.24% | +3.34% |
| Weighted Average Shares Diluted Growth | +1.86% | +1.58% | +1.47% | +1.88% | +5.12% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -213.24% | +0.00% | -216.90% | +0.00% | +0.00% |
| Free Cash Flow Growth | -343.43% | +0.00% | -233.97% | +0.00% | +0.00% |
| Receivables Growth | +15.37% | +15.56% | +24.27% | +16.07% | +14.05% |
| Inventory Growth | +98.98% | +117.93% | +90.45% | +54.27% | +92.64% |
| Asset Growth | +0.92% | +9.43% | +8.78% | +10.46% | +21.00% |
| Book Value per Share Growth | +18.94% | +45.80% | +51.92% | +27.28% | +36.76% |
| Debt Growth | -0.32% | -0.23% | -0.17% | -0.41% | +8.94% |
| R&D Expense Growth | -13.81% | -1.73% | +146.52% | -10.49% | -21.36% |
| SG&A Expenses Growth | +23.39% | +4.31% | +14.91% | +19.88% | +35.09% |